A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer Over-expressing the c-Met Protein.
Phase of Trial: Phase I
Latest Information Update: 07 Jul 2017
At a glance
- Drugs ARGX 111 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors argenx
- 07 Jul 2017 Results published in an Argenx media release.
- 07 Jul 2017 According to an Argenx media release, abstract covering the complete data set from this trial was presented at American Society of Clinical Oncology (ASCO) program at the 3rd Singapore Society of Oncology Annual Scientific Meeting.
- 10 Jun 2017 Biomarkers information updated
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History